To systematically evaluate the clinical efficacy and safety of Ruanjian Sanjie Chinese medicines in the treatment of patients with non-small cell lung cancer.Methods:We used computer search in Chinese Biomedical Literature Database(CBM),China Journal Full-text Database(CJFD),Chinese Sci-tech Journal Database(CCD),Pubmed,Cochrane library database,etc.from the establishment of the database to the publication in September 2018.We searched Clinical Randomized Controlled Research Literature by using Chinese Medicinals to treat middle and advanced lung cancer with Ruanjian Sanjie Chinese medicines.The bias risk assessment tool of the Cochrane systematic review manual and the Jadad scale were used to evaluate the quality of the literature; for the methodological evaluation,heterogeneity test,sensitivity analysis,etc.we used RevMan5.0 software.Results:A total of 13 RCTs with 1123 patients were included.Meta-analysis results showed that the efficacy of Ruanjian Sanjie Chinese medicines combined with chemotherapy was significantly better than simple chemotherapy.It was mainly manifested in short-term efficacy,quality of life,and clinical improvement of symptoms.But there was no advantage in reducing the safety of bone marrow toxicity and the adverse reactions of nausea and vomiting.The combination of Ruanjian Sanjie Chinese medicines was superior to chemotherapy in terms of short-term efficacy.But it had no advantages in reducing bone marrow toxicity,inhibiting the decline of white blood cells and platelets,and the adverse reactions of nausea and vomiting.Conclusion:Chemotherapy assisted by Ruanjian Sanjie Chinese medicines has a better effect for advanced lung cancer.